Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998;77(2):260–269. doi: 10.1038/bjc.1998.42

Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.

A M Björkqvist 1, L Tammilehto 1, S Nordling 1, M Nurminen 1, S Anttila 1, K Mattson 1, S Knuutila 1
PMCID: PMC2151225  PMID: 9460997

Abstract

The differential diagnosis of mesothelioma, primary adenocarcinomas and pleural metastases frequently causes problems. We have used the comparative genomic hybridization (CGH) technique on 34 malignant mesotheliomas and 30 primary lung carcinomas (adenocarcinoma, including bronchoalveolar carcinoma and large-cell anaplastic carcinoma) to compare their copy number changes and to evaluate the use of CGH to distinguish between these two types of tumour. In mesothelioma, gains of genetic material occurred as frequently as losses, whereas gains predominated over losses in carcinoma. In mesothelioma, the most frequent changes were losses in 4q, 6q and 14q and gains in 15q and 7p, whereas gains in 8q, 1q, 7p, 5p and 6p were the most common changes in carcinoma. Amplification of KRAS2 was detected in two adenocarcinomas by Southern blot analysis. CGH showed gains in 12p in the same tumours. Statistically significant differences between the two types of tumour were detected in chromosomes X, 1, 2p, 4, 8q, 10q, 12p, 14q, 15q and 18q. When comparing the frequency of gains and losses between mesothelioma and lung carcinoma using discriminant analysis, the sensitivity of CGH to differentiate mesotheliomas from lung carcinomas was 81% and the specificity 77%. The differences in DNA copy number changes between the two types of tumour suggest that they are genetically different tumour entities. Although CGH cannot be used as a definitive discriminatory method, we were able to distinguish between mesothelioma and lung carcinoma in a large proportion of the abnormal cases.

Full text

PDF
260

Images in this article

266Figure 3
on p.266

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björkqvist A. M., Tammilehto L., Anttila S., Mattson K., Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer. 1997;75(4):523–527. doi: 10.1038/bjc.1997.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brown R. W., Clark G. M., Tandon A. K., Allred D. C. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993 Apr;24(4):347–354. doi: 10.1016/0046-8177(93)90080-z. [DOI] [PubMed] [Google Scholar]
  3. Chahinian A. P., Pajak T. F., Holland J. F., Norton L., Ambinder R. M., Mandel E. M. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982 Jun;96(6 Pt 1):746–755. doi: 10.7326/0003-4819-96-6-746. [DOI] [PubMed] [Google Scholar]
  4. Cline M. J., Battifora H. Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. Cancer. 1987 Dec 1;60(11):2669–2674. doi: 10.1002/1097-0142(19871201)60:11<2669::aid-cncr2820601116>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  5. Doglioni C., Dei Tos A. P., Laurino L., Iuzzolino P., Chiarelli C., Celio M. R., Viale G. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996 Sep;20(9):1037–1046. doi: 10.1097/00000478-199609000-00001. [DOI] [PubMed] [Google Scholar]
  6. Edwards C., Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. J Clin Pathol. 1995 Jul;48(7):626–630. doi: 10.1136/jcp.48.7.626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hagemeijer A., Versnel M. A., Van Drunen E., Moret M., Bouts M. J., van der Kwast T. H., Hoogsteden H. C. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990 Jul 1;47(1):1–28. doi: 10.1016/0165-4608(90)90258-c. [DOI] [PubMed] [Google Scholar]
  8. Harrell F. E., Jr, Lee K. L., Mark D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996 Feb 28;15(4):361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  9. Hirvonen A., Saarikoski S. T., Linnainmaa K., Koskinen K., Husgafvel-Pursiainen K., Mattson K., Vainio H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst. 1996 Dec 18;88(24):1853–1856. doi: 10.1093/jnci/88.24.1853. [DOI] [PubMed] [Google Scholar]
  10. Isola J., DeVries S., Chu L., Ghazvini S., Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol. 1994 Dec;145(6):1301–1308. [PMC free article] [PubMed] [Google Scholar]
  11. Jin Y. S., Mandahl N., Heim S., Schüller H., Mitelman F. Isochromosomes i(8q) or i(9q) in three adenocarcinomas of the lung. Cancer Genet Cytogenet. 1988 Jul 1;33(1):11–17. doi: 10.1016/0165-4608(88)90043-x. [DOI] [PubMed] [Google Scholar]
  12. Kallioniemi O. P., Kallioniemi A., Piper J., Isola J., Waldman F. M., Gray J. W., Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994 Aug;10(4):231–243. doi: 10.1002/gcc.2870100403. [DOI] [PubMed] [Google Scholar]
  13. Kivipensas P., Björkqvist A. M., Karhu R., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Kallioniemi Q. P., Knuutila S. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet. 1996 Jul 1;89(1):7–13. doi: 10.1016/0165-4608(95)00358-4. [DOI] [PubMed] [Google Scholar]
  14. Lukeis R., Ball D., Irving L., Garson O. M., Hasthorpe S. Chromosome abnormalities in non-small cell lung cancer pleural effusions: cytogenetic indicators of disease subgroups. Genes Chromosomes Cancer. 1993 Dec;8(4):262–269. doi: 10.1002/gcc.2870080409. [DOI] [PubMed] [Google Scholar]
  15. Lukeis R., Irving L., Garson M., Hasthorpe S. Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer. 1990 Jul;2(2):116–124. doi: 10.1002/gcc.2870020207. [DOI] [PubMed] [Google Scholar]
  16. Metcalf R. A., Welsh J. A., Bennett W. P., Seddon M. B., Lehman T. A., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B. I. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992 May 1;52(9):2610–2615. [PubMed] [Google Scholar]
  17. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat Med. 1985 Apr-Jun;4(2):213–226. doi: 10.1002/sim.4780040211. [DOI] [PubMed] [Google Scholar]
  18. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Monni O., Joensuu H., Franssila K., Knuutila S. DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study. Blood. 1996 Jun 15;87(12):5269–5278. [PubMed] [Google Scholar]
  20. Peltomäki P., Alfthan O., de la Chapelle A. Oncogenes in human testicular cancer: DNA and RNA studies. Br J Cancer. 1991 Jun;63(6):851–858. doi: 10.1038/bjc.1991.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pisani R. J., Colby T. V., Williams D. E. Malignant mesothelioma of the pleura. Mayo Clin Proc. 1988 Dec;63(12):1234–1244. doi: 10.1016/s0025-6196(12)65411-1. [DOI] [PubMed] [Google Scholar]
  22. Skov B. G., Lauritzen A. F., Hirsch F. R., Skov T., Nielsen H. W. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Histopathology. 1994 Nov;25(5):431–437. doi: 10.1111/j.1365-2559.1994.tb00004.x. [DOI] [PubMed] [Google Scholar]
  23. Slebos R. J., Evers S. G., Wagenaar S. S., Rodenhuis S. Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. Br J Cancer. 1989 Jan;59(1):76–80. doi: 10.1038/bjc.1989.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Taguchi T., Jhanwar S. C., Siegfried J. M., Keller S. M., Testa J. R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 1993 Sep 15;53(18):4349–4355. [PubMed] [Google Scholar]
  25. Testa J. R., Siegfried J. M., Liu Z., Hunt J. D., Feder M. M., Litwin S., Zhou J. Y., Taguchi T., Keller S. M. Cytogenetic analysis of 63 non-small cell lung carcinomas: recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chromosomes Cancer. 1994 Nov;11(3):178–194. doi: 10.1002/gcc.2870110307. [DOI] [PubMed] [Google Scholar]
  26. Tiainen M., Tammilehto L., Rautonen J., Tuomi T., Mattson K., Knuutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer. 1989 Oct;60(4):618–626. doi: 10.1038/bjc.1989.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Weiss L. M., Battifora H. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. Hum Pathol. 1993 Apr;24(4):345–346. doi: 10.1016/0046-8177(93)90079-v. [DOI] [PubMed] [Google Scholar]
  28. Xiao S., Li D., Corson J. M., Vijg J., Fletcher J. A. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 1995 Jul 15;55(14):2968–2971. [PubMed] [Google Scholar]
  29. Xio S., Li D., Vijg J., Sugarbaker D. J., Corson J. M., Fletcher J. A. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995 Aug 3;11(3):511–515. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES